Stock Price Quote

NATH BIO-GENES (INDIA) LTD.

NSE : NATHBIOGENBSE : 537291ISIN CODE : INE448G01010Industry : AgricultureHouse : Private
BSE149.700.6 (+0.4 %)
PREV CLOSE ( ) 149.10
OPEN PRICE ( ) 150.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 238
TODAY'S LOW / HIGH ( )146.30 150.55
52 WK LOW / HIGH ( )138 238
NSE150.061.39 (+0.93 %)
PREV CLOSE( ) 148.67
OPEN PRICE ( ) 150.79
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6451
TODAY'S LOW / HIGH( ) 148.20 152.00
52 WK LOW / HIGH ( )136 238.69
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 13-09 2000
Management Info
- Chairman Satish Kagliwal - Managing Director
Registered Office

Address Nath House, Nath Road,P B No 318,,
Chhatrapati Sambhajinagar - (Aurangabad),
Maharashtra-431005

Phone 0240-2376314-7

Email info@nathseeds.com / investor@nathbiogenes.com

Website www.nathbiogenes.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

01Feb Nath Bio-Genes (India) informs about p
Nath Bio-Genes (India) has informed that it attached, presentation on Un..
14Nov Nath Bio-Genes (India) informs about p
Nath Bio-Genes (India) has attached presentation on Unaudited financial..
14Nov Nath Bio-Genes (India) informs about p
Nath Bio-Genes (India) has informed that it attached, presentation on Un..
24Apr Nath Bio-Genes (India) informs about c
Nath Bio-Genes (India) has informed that the Company will hold Earning C..
19Oct Nath Bio-Genes (India) submits analyst
Nath Bio-Genes (India) has informed that the Company will hold Earning C..

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit72.2999999999999421.4
Gross Profit 81.0299999999999 435.85
Operating Profit 105.7570.21
Net Sales 659.613623.08

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Indo US Bio-Tech (BSE)
peergroup  150.15 (4.02%)
M.Cap ( in Cr)301.08
Times Green Energy (BSE)
peergroup  86.50 (4.59%)
M.Cap ( in Cr)24.11
Kaveri Seed (BSE)
peergroup  845.70 (0.39%)
M.Cap ( in Cr)4350.20
Venkys India (BSE)
peergroup  1423.35 (0.20%)
M.Cap ( in Cr)2005.12
Mangalam Seeds (BSE)
peergroup  137.00 (2.01%)
M.Cap ( in Cr)150.43

Shareholding Pattern

NON-INSTITUTION 54.08%
PROMOTERS 45.6%
MUTUAL FUNDS/UTI 0.01%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Nath Bio-Genes (India) Ltd.

Nath Bio-Genes (India) Ltd. was incorporated in the year 2000. Its today's share price is 149.7. Its current market capitalisation stands at Rs 284.49 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3623.08 Cr and Total Income of Rs.3670.36 Cr. The company's management includes Dhiraj Rathi, Shipra Agrawal, Madhukar Deshpande, Vadla Nagbhushanam, Hitesh Purohit, Akash Kagliwal, Jeevanlata Kagliwal, Satish Kagliwal.

It is listed on the BSE with a BSE Code of 537291 , NSE with an NSE Symbol of NATHBIOGEN and ISIN of INE448G01010. It's Registered office is at Nath House, Nath Road,P B No 318,Chhatrapati Sambhajinagar - (Aurangabad)-431005, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Ashok R Majethia & Co, Gautam N Associates, Gutam N Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.